{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:53:26Z","timestamp":1794369206471,"version":"4.9.0"},"reference-count":118,"publisher":"Elsevier","isbn-type":[{"value":"9780443188800","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.apha.2023.05.001","type":"book-chapter","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T19:58:38Z","timestamp":1685131118000},"page":"55-81","source":"Crossref","is-referenced-by-count":15,"title":["Phosphodiesterase inhibitors and lung diseases"],"prefix":"10.1016","author":[{"given":"Ivana","family":"Stolfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bcpt.12209","article-title":"Dual PDE3\/4 and PDE4 inhibitors: Novel treatments for COPD and other inflammatory airway diseases","volume":"114","author":"Abbott-Banner","year":"2014","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/jm401549m","article-title":"Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases","volume":"57","author":"Armani","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.apha.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: Inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.apha.2023.05.001_bib4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1183\/09031936.95.08060996","article-title":"Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma","author":"Banner","year":"1995","journal-title":"European Respiratory Journal"},{"key":"10.1016\/bs.apha.2023.05.001_bib5","first-page":"332","article-title":"Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers","volume":"287","author":"Barber","year":"2004","journal-title":"American Journal of"},{"issue":"6","key":"10.1016\/bs.apha.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline: New perspectives for an old drug","volume":"167","author":"Barnes","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2023.05.001_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4025","article-title":"New anti-inflammatory targets for chronic obstructive pulmonary disease","volume":"12","author":"Barnes","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"8","key":"10.1016\/bs.apha.2023.05.001_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/bs.apha.2023.05.001_bib9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014Still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.nano.2015.08.009","article-title":"Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension","volume":"12","author":"Beck-Broichsitter","year":"2016","journal-title":"Nanomedicine: Nanotechnology, Biology, and Medicine"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2023.05.001_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijpharm.2011.10.012","article-title":"Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb\u00ae Pro: Formulation aspects and nanoparticle stability to nebulization","volume":"422","author":"Beck-Broichsitter","year":"2012","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jconrel.2011.09.058","article-title":"Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters","volume":"157","author":"Beck-Broichsitter","year":"2012","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/bs.apha.2023.05.001_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jconrel.2011.10.030","article-title":"Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery","volume":"158","author":"Beck-Broichsitter","year":"2012","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/bs.apha.2023.05.001_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"Boswell-Smith","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"9691","key":"10.1016\/bs.apha.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.113.204644","article-title":"Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone","volume":"346","author":"Calzetta","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"148","key":"10.1016\/bs.apha.2023.05.001_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2018","article-title":"Efficacy and safety profile of xanthines in COPD: A network meta-analysis","volume":"27","author":"Cazzola","year":"2018","journal-title":"European Respiratory Review"},{"issue":"10","key":"10.1016\/bs.apha.2023.05.001_bib18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/13543784.2019.1661990","article-title":"Ensifentrine (RPL554): An investigational PDE3\/4 inhibitor for the treatment of COPD","volume":"28","author":"Cazzola","year":"2019","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01675-2018","article-title":"An inhaled \u201cbifunctional\u201d dual PDE3\/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: Implications for future treatment of COPD","volume":"52","author":"Cazzola","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1016\/bs.apha.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4155\/ppa-2018-0030","article-title":"Ensifentrine (RPL554): An inhaled \u201cbifunctional\u201d dual PDE3\/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"7","author":"Cazzola","year":"2018","journal-title":"Pharmaceutical Patent Analyst"},{"issue":"23","key":"10.1016\/bs.apha.2023.05.001_bib21","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMe2205411","article-title":"Preferential PDE4B inhibition\u2014A step toward a new treatment for idiopathic pulmonary fibrosis","volume":"386","author":"Chambers","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.coph.2011.09.002","article-title":"PDE1 isozymes, key regulators of pathological vascular remodeling","volume":"11","author":"Chan","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1183\/09031936.00102610","article-title":"Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma","volume":"39","author":"Chevalier","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1016\/bs.apha.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annual Review of Biochemistry"},{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"Journal of Experimental Medicine"},{"issue":"8","key":"10.1016\/bs.apha.2023.05.001_bib26","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1021\/acs.biomac.2c00576","article-title":"Inhalable formulation based on lipid\u2013polymer hybrid nanoparticles for the macrophage targeted delivery of roflumilast","volume":"23","author":"Craparo","year":"2022","journal-title":"Biomacromolecules"},{"issue":"10","key":"10.1016\/bs.apha.2023.05.001_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/bs.apha.2023.05.001_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cellsig.2017.08.011","article-title":"Identification and characterization of a potent and biologically-active PDE4\/7 inhibitor via fission yeast-based assays","volume":"40","author":"de Medeiros","year":"2017","journal-title":"Cellular Signalling"},{"issue":"11","key":"10.1016\/bs.apha.2023.05.001_bib29","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1021\/jm5001216","article-title":"Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD","volume":"57","author":"de Savi","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2023.05.001_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2019.01.068","article-title":"TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model","volume":"849","author":"Demizu","year":"2019","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib31","unstructured":"European Medicines Agency. (2010). CHMP assessment report- Daxas. \u3008www.ema.europa.eu\u3009."},{"key":"10.1016\/bs.apha.2023.05.001_bib32","first-page":"12","article-title":"Tanimilast, a Novel inhaled PDE-4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","author":"Facchinetti","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.772704","article-title":"Doxofylline for pediatric asthma steps 1\u20134. Pediatric asthma: New role for an old drug","volume":"10","author":"Fierro","year":"2022","journal-title":"Frontiers in Pediatrics"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jamp.2017.1369","article-title":"Investigation of lung pharmacokinetic of the novel PDE4 inhibitor CHF6001 in preclinical models: Evaluation of the preciseinhale technology","volume":"31","author":"Fioni","year":"2018","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/COPD.S10770","article-title":"Pathogenic triad in COPD: Oxidative stress, protease-antiprotease imbalance, and inflammation","volume":"6","author":"Fischer","year":"2011","journal-title":"International Journal of COPD"},{"key":"10.1016\/bs.apha.2023.05.001_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-10-39","article-title":"A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice","volume":"10","author":"Fortin","year":"2009","journal-title":"Respiratory Research"},{"issue":"9","key":"10.1016\/bs.apha.2023.05.001_bib37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: Findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"The Lancet Respiratory Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2023.05.001_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.apha.2023.05.001_bib39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1165\/ajrcmb.20.2.3140","article-title":"Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells","volume":"20","author":"Fuhrmann","year":"1999","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/bbrc.2000.2743","article-title":"Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase","volume":"272","author":"Gardner","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"12","key":"10.1016\/bs.apha.2023.05.001_bib41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0165-6147(02)02089-8","article-title":"4D or not 4D\u2014The ematogenic basis of PDE4 inhibitors uncovered?","volume":"23","author":"Giembycz","year":"2022","journal-title":"Trends in Pharmacological Sciences"},{"issue":"8","key":"10.1016\/bs.apha.2023.05.001_bib42","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/j.1476-5381.1996.tb15629.x","article-title":"Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2","volume":"118","author":"Giembycz","year":"1996","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib43","doi-asserted-by":"crossref","unstructured":"Giembycz, M. A., & Newton, R. (2011). Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies. In Handbook of Experimental Pharmacology (Vol. 204, 415\u2013446). \u3008http:\/\/www.springer.com\/series\/164\u3009.","DOI":"10.1007\/978-3-642-17969-3_18"},{"key":"10.1016\/bs.apha.2023.05.001_bib44","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. (2023)."},{"issue":"12","key":"10.1016\/bs.apha.2023.05.001_bib45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast\u2014A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib47","first-page":"267","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2023.05.001_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1073\/pnas.97.1.472","article-title":"Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase","volume":"97","author":"Hetman","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.pupt.2008.02.002","article-title":"Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial","volume":"21","author":"Hohlfeld","year":"2008","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1016\/bs.apha.2023.05.001_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021698","article-title":"PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"The Biochemical Journal"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib52","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1183\/09031936.96.09030456","article-title":"Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics","volume":"9","author":"Jaffar","year":"1996","journal-title":"European Respiratory Journal"},{"key":"10.1016\/bs.apha.2023.05.001_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/0929867324666170116125159","article-title":"PDE7-selective and dual inhibitors: Advances in chemical and biological research","volume":"24","author":"Jankowska","year":"2017","journal-title":"Current Medicinal Chemistry"},{"issue":"6","key":"10.1016\/bs.apha.2023.05.001_bib54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03338-2020","article-title":"The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: The TASCS randomised controlled trial","volume":"57","author":"Jenkins","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1016\/bs.apha.2023.05.001_bib55","doi-asserted-by":"crossref","unstructured":"Ke, H., Wang, H., & Ye, M. (2011). Structural Insights into the Substrate Specificity of Phosphodiesterases. In Handbook of Experimental Pharmacology (Vol. 204, 121\u2013132). \u3008https:\/\/doi.org\/10.1007\/978.3.642.13443.2\u3009.","DOI":"10.1007\/978-3-642-17969-3_4"},{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib56","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17425247.2020.1729119","article-title":"Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension","volume":"17","author":"Keshavarz","year":"2020","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12272-021-01367-x","article-title":"The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model","volume":"45","author":"Kim","year":"2022","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/bs.apha.2023.05.001_bib59","doi-asserted-by":"crossref","DOI":"10.2332\/allergolint.08-OA-0053","article-title":"Effects of KF19514, a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma","volume":"58","author":"Kita","year":"2009","journal-title":"Allergology International"},{"issue":"2","key":"10.1016\/bs.apha.2023.05.001_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.yjmcc.2011.05.002","article-title":"AKAPs: The architectural underpinnings of local cAMP signaling","volume":"52","author":"Kritzer","year":"2012","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"21","key":"10.1016\/bs.apha.2023.05.001_bib61","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1021\/bi992432w","article-title":"Conformational difference between PDE4 apoenzyme and holoenzyme","volume":"39","author":"Lalibert\u00e9","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/bs.apha.2023.05.001_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjp.0704120","article-title":"Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects","volume":"133","author":"Landells","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib63","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jconrel.2022.08.021","article-title":"Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review","volume":"350","author":"Lazo","year":"2022","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/bs.apha.2023.05.001_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154739","article-title":"The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients","volume":"123","author":"Lea","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/bs.apha.2023.05.001_bib65","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.283.5403.848","article-title":"CD3- and CD28-dependent induction of PDE7 required for T cell activation","volume":"283","author":"Li","year":"1999","journal-title":"Science (New York, N. Y.)"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib66","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00240-2022","article-title":"Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis","volume":"8","author":"Maher","year":"2022","journal-title":"ERJ Open Research"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2023.05.001_bib67","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijpharm.2016.12.026","article-title":"Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor","volume":"517","author":"Makled","year":"2017","journal-title":"International Journal of Pharmaceutics"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1006\/pupt.1999.0224","article-title":"The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs","volume":"13","author":"Manabe","year":"2000","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1016\/bs.apha.2023.05.001_bib69","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.2147\/COPD.S174156","article-title":"Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: Two randomized trials in healthy volunteers","volume":"13","author":"Mariotti","year":"2018","journal-title":"International Journal of COPD"},{"key":"10.1016\/bs.apha.2023.05.001_bib70","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2147\/COPD.S226688","article-title":"Inhaled dual phosphodiesterase 3\/4 inhibitors for the treatment of patients with COPD: A short review","volume":"16","author":"Martin","year":"2021","journal-title":"International Journal of COPD"},{"key":"10.1016\/bs.apha.2023.05.001_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/JEP.S242961","article-title":"New avenues for phosphodiesterase inhibitors in asthma","volume":"13","author":"Matera","year":"2021","journal-title":"Journal of Experimental Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib72","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.2147\/COPD.S150887","article-title":"Doxofylline is not just another theophylline!","volume":"12","author":"Matera","year":"2017","journal-title":"International Journal of COPD"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"17","key":"10.1016\/bs.apha.2023.05.001_bib74","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1016\/S0021-9258(18)31474-1","article-title":"Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of CAMP phosphodiesterase-deficient Saccharomyces cerevisiae\u204e","volume":"268","author":"Michaeli","year":"1993","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib75","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.114.220541","article-title":"CHF6001 II: A novel highly potent phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary delivery","volume":"352","author":"Moretto","year":"2015","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib76","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2222.2000.00782.x","article-title":"Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs","volume":"30","author":"Myou","year":"2000","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/bs.apha.2023.05.001_bib77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2249.2002.01856.x","article-title":"Potential role of phosphodiesterase 7 in human T cell function: Comparative effects of two phosphodiesterase inhibitors","volume":"128","author":"Nakata","year":"2002","journal-title":"Clinical and Experimental Immunology"},{"issue":"5","key":"10.1016\/bs.apha.2023.05.001_bib78","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/thx.2004.024463","article-title":"Inflammatory cells in the airways in COPD","volume":"61","author":"O\u2019Donnell","year":"2006","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/bs.apha.2023.05.001_bib79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pupt.2010.04.002","article-title":"Doxofylline: A novofylline","volume":"23","author":"Page","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000368800","article-title":"Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease","volume":"165","author":"Page","year":"2014","journal-title":"International Archives of Allergy and Immunology"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib81","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/bs.apha.2023.05.001_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2023.05.001_bib83","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","article-title":"Apremilast: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00441-003-0728-y","article-title":"Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils","volume":"312","author":"Pryzwansky","year":"2003","journal-title":"Cell and Tissue Research"},{"key":"10.1016\/bs.apha.2023.05.001_bib85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast\u2014An oral anti-inflammatory treatment of chronic obstructive pulmonary disease: A randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/bs.apha.2023.05.001_bib86","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0021-9258(19)77422-5","article-title":"Formation of a cyclic adenine ribonucleotide by tissue particles\u204e","volume":"232","author":"Rall","year":"1958","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2023.05.001_bib87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.02.003","article-title":"Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH","volume":"250","author":"Rashid","year":"2017","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/bs.apha.2023.05.001_bib88","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2023.05.001_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.10.008","article-title":"Steroid sparing effects of doxofylline","volume":"48","author":"Riffo-Vasquez","year":"2018","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1016\/bs.apha.2023.05.001_bib90","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","article-title":"PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway","volume":"40","author":"Robichaud","year":"2001","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2023.05.001_bib91","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens \u03b12-adrenoceptor\u2013mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s40248-019-0189-0","article-title":"Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis","volume":"14","author":"Rogliani","year":"2019","journal-title":"Multidisciplinary Respiratory Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1006\/bbrc.2000.2661","article-title":"Identification of human PDE7B, a cAMP-specific phosphodiesterase","volume":"271","author":"Sasaki","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9","key":"10.1016\/bs.apha.2023.05.001_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094982","article-title":"The PDE4 inhibitor tanimilast restrains the tissue\u2010damaging properties of human neutrophils","volume":"23","author":"Schioppa","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apha.2023.05.001_bib95","first-page":"241","article-title":"Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family","volume":"Vol. 66","author":"Shakur","year":"2000"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib96","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05163-2","article-title":"Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): Study protocol for a randomized controlled trial","volume":"22","author":"Siddharthan","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respiratory Research"},{"issue":"16","key":"10.1016\/bs.apha.2023.05.001_bib98","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/bs.apha.2023.05.001_bib99","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00170.2002","article-title":"Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells","author":"Smith","year":"2003","journal-title":"American Journal of Physiology\u2014Lung Cellular and Molecular Physiology, 284(2 28-2)"},{"issue":"6","key":"10.1016\/bs.apha.2023.05.001_bib100","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib101","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2018.06.007","article-title":"Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients","volume":"113","author":"Southworth","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/bs.apha.2023.05.001_bib102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1146\/annurev.pharmtox.41.1.751","article-title":"Compartmentation of G protein-coupled signaling pathways in cardiac myocytes","volume":"41","author":"Steinberg","year":"2001","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"17","key":"10.1016\/bs.apha.2023.05.001_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21176118","article-title":"Role of phosphodiesterase 7 (PDE7) in T cell activity. Effects of selective PDE7 inhibitors and dual PDE4\/7 inhibitors on T cell functions","volume":"21","author":"Szczypka","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/bs.apha.2023.05.001_bib104","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2222.1995.tb01109.x","article-title":"Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes","volume":"25","author":"Tenor","year":"1995","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/bs.apha.2023.05.001_bib105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"State of the art phosphodiesterase isozymes molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/bs.apha.2023.05.001_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.702677","article-title":"Type-4 phosphodiesterase (PDE4) blockade reduces NETosis in cystic fibrosis","volume":"12","author":"Totani","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107826","article-title":"Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis","volume":"224","author":"Turner","year":"2021","journal-title":"Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib108","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.120.000080","article-title":"The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4","volume":"375","author":"Turner","year":"2020","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2023.05.001_bib109","first-page":"908","article-title":"The dual phosphodiesterase 3\/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants","volume":"318","author":"Turner","year":"2020","journal-title":"American Journal of"},{"key":"10.1016\/bs.apha.2023.05.001_bib110","first-page":"59","article-title":"The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia","volume":"310","author":"Turner","year":"2016","journal-title":"American Journal of"},{"issue":"1","key":"10.1016\/bs.apha.2023.05.001_bib111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pupt.2011.10.007","article-title":"The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism","volume":"25","author":"van Mastbergen","year":"2012","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2023.05.001_bib112","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.114.220558","article-title":"CHF6001 II: A novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration\u2014In vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window","volume":"352","author":"Villetti","year":"2015","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"30","key":"10.1016\/bs.apha.2023.05.001_bib113","doi-asserted-by":"crossref","first-page":"21469","DOI":"10.1074\/jbc.M512527200","article-title":"Multiple conformations of phosphodiesterase-5: Implications for enzyme function and drug development","volume":"281","author":"Wang","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2023.05.001_bib114","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/mol.56.1.170","article-title":"Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils","volume":"56","author":"Wang","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.preteyeres.2016.06.002","article-title":"Structural and molecular bases of rod photoreceptor morphogenesis and disease","volume":"55","author":"Wensel","year":"2016","journal-title":"Progress in Retinal and Eye Research"},{"key":"10.1016\/bs.apha.2023.05.001_bib116","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1152\/ajplung.1998.275.4.L694","article-title":"Phosphodiesterase expression in human epithelial cells","volume":"19","author":"Wright","year":"1998","journal-title":"Lung Cellular and Molecular Physiology"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2023.05.001_bib117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejphar.2006.08.023","article-title":"Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models","volume":"550","author":"Yamamoto","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.apha.2023.05.001_bib118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacology and Therapeutics"}],"container-title":["Advances in Pharmacology","Pulmonary Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358923000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358923000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:31:38Z","timestamp":1715315498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358923000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443188800"],"references-count":118,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2023.05.001","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}